Ascendis Pharma As Stock Today
| ASND Stock | USD 166.05 1.40 0.85% |
PerformanceOK
| Odds Of DistressLow
|
Ascendis Pharma is trading at 166.05 as of the 20th of March 2025, a 0.85 percent up since the beginning of the trading day. The stock's lowest day price was 161.01. Ascendis Pharma has less than a 17 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Ascendis Pharma AS, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark. Ascendis Pharma is traded on NASDAQ Exchange in the United States. The company has 60.09 M outstanding shares of which 3.63 M shares are presently shorted by private and institutional investors with about 7.98 trading days to cover. More on Ascendis Pharma AS
Moving against Ascendis Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Ascendis Stock Highlights
| CEO | Jan Mikkelsen |
| Business Concentration | Pharmaceutical Products, Biotechnology, Healthcare, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Ascendis Pharma AS (ASND) is traded on NASDAQ Exchange in USA. It is located in Tuborg Boulevard 12, Hellerup, Denmark, 2900 and employs 1,017 people. Ascendis Pharma is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 9.89 B. Ascendis Pharma AS conducts business under Biotechnology sector and is part of Health Care industry. The entity has 60.09 M outstanding shares of which 3.63 M shares are presently shorted by private and institutional investors with about 7.98 trading days to cover.
Ascendis Pharma AS currently holds about 955.15 M in cash with (306.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 17.11.
Check Ascendis Pharma Probability Of Bankruptcy
Ownership AllocationThe majority of Ascendis Pharma AS outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Ascendis Pharma AS to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Ascendis Pharma. Please pay attention to any change in the institutional holdings of Ascendis Pharma AS as this could imply that something significant has changed or is about to change at the company.
Check Ascendis Ownership Details
Ascendis Pharma AS Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Ascendis Pharma market risk premium is the additional return an investor will receive from holding Ascendis Pharma long position in a well-diversified portfolio.
| Risk Adjusted Performance | 0.1068 | |||
| Jensen Alpha | 0.3404 | |||
| Total Risk Alpha | 0.6649 | |||
| Sortino Ratio | 0.1767 |
Ascendis Stock Against Markets
Ascendis Pharma Corporate Management
| Michael LLM | Chief VP | Profile | |
| Birgitte MD | Sr Affairs | Profile | |
| Stina MD | Executive Oncology | Profile | |
| Scott Holmes | Head Endocrinology | Profile | |
| Timothy Lee | Director Relations | Profile | |
| Nyssa Noyola | Vice Management | Profile | |
| Jens Okkels | VP Devel | Profile |
Already Invested in Ascendis Pharma AS?
The danger of trading Ascendis Pharma AS is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Ascendis Pharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Ascendis Pharma. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Ascendis Pharma AS is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Ascendis Pharma AS is a strong investment it is important to analyze Ascendis Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ascendis Pharma's future performance. For an informed investment choice regarding Ascendis Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ascendis Pharma AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ascendis Pharma. If investors know Ascendis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ascendis Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Ascendis Pharma AS is measured differently than its book value, which is the value of Ascendis that is recorded on the company's balance sheet. Investors also form their own opinion of Ascendis Pharma's value that differs from its market value or its book value, called intrinsic value, which is Ascendis Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ascendis Pharma's market value can be influenced by many factors that don't directly affect Ascendis Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ascendis Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ascendis Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ascendis Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.